Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-945-5576
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.73 million
Profitability
Miscellaneous
Employees56
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable
Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions
What is Unum Therapeutics' stock symbol?
Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."
How were Unum Therapeutics' earnings last quarter?
Unum Therapeutics Inc (NASDAQ:UMRX) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.08. The firm had revenue of $3.05 million for the quarter, compared to analysts' expectations of $3.15 million. Unum Therapeutics had a negative return on equity of 62.24% and a negative net margin of 373.81%. View Unum Therapeutics' Earnings History.
When is Unum Therapeutics' next earnings date?
What price target have analysts set for UMRX?
5 brokerages have issued 1 year price targets for Unum Therapeutics' stock. Their predictions range from $10.00 to $21.00. On average, they anticipate Unum Therapeutics' stock price to reach $17.25 in the next twelve months. This suggests a possible upside of 627.8% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.
What is the consensus analysts' recommendation for Unum Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.
What are Wall Street analysts saying about Unum Therapeutics stock?
Here are some recent quotes from research analysts about Unum Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our price target of $18/share is based on an equally-weighted composite of: (a) $18.2/share, as a 25x multiple of taxed and diluted $7.75 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.3/share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (5/14/2019)
- 2. According to Zacks Investment Research, "Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. " (4/26/2019)
Has Unum Therapeutics been receiving favorable news coverage?
Press coverage about UMRX stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Unum Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Unum Therapeutics.
Are investors shorting Unum Therapeutics?
Unum Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 912,200 shares, a decrease of 6.7% from the April 15th total of 978,200 shares. Based on an average daily volume of 87,500 shares, the short-interest ratio is presently 10.4 days. Currently, 5.0% of the company's shares are short sold. View Unum Therapeutics' Current Options Chain.
Who are some of Unum Therapeutics' key competitors?
Some companies that are related to Unum Therapeutics include BELLUS Health (BLUSF), Kindred Biosciences (KIN), ImmunoGen (IMGN), Merus (MRUS), Cyclerion Therapeutics (CYCN), AMAG Pharmaceuticals (AMAG), Geron (GERN), Syros Pharmaceuticals (SYRS), Zynerba Pharmaceuticals (ZYNE), Evelo Biosciences (EVLO), TapImmune (MRKR), OptiNose (OPTN), Immune Design (IMDZ), Molecular Templates (MTEM) and Xeris Pharmaceuticals (XERS).
What other stocks do shareholders of Unum Therapeutics own?
Who are Unum Therapeutics' key executives?
Unum Therapeutics' management team includes the folowing people:
- Dr. Charles Wilson, CEO, Pres & Director (Age 54)
- Mr. Michael J. Vasconcelles, Chief Medical Officer (Age 55)
- Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
- Mr. John L. Green, VP of Fin. (Age 39)
- Mr. Geoffrey Hodge, Chief Technical Officer & Sr. VP of Operations (Age 54)
When did Unum Therapeutics IPO?
(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.
Who are Unum Therapeutics' major shareholders?
Unum Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (1.33%), Wasatch Advisors Inc. (0.84%) and Rhumbline Advisers (0.06%). Company insiders that own Unum Therapeutics stock include Liam Ratcliffe, Seth Ettenberg and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Unum Therapeutics.
Which institutional investors are selling Unum Therapeutics stock?
Which institutional investors are buying Unum Therapeutics stock?
UMRX stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc. and Rhumbline Advisers. Company insiders that have bought Unum Therapeutics stock in the last two years include Liam Ratcliffe and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Unum Therapeutics.
How do I buy shares of Unum Therapeutics?
Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Unum Therapeutics' stock price today?
One share of UMRX stock can currently be purchased for approximately $2.37.
How big of a company is Unum Therapeutics?
Unum Therapeutics has a market capitalization of $71.38 million and generates $9.73 million in revenue each year. The company earns $-34,530,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Unum Therapeutics employs 56 workers across the globe.View Additional Information About Unum Therapeutics.
What is Unum Therapeutics' official website?
How can I contact Unum Therapeutics?
Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]
MarketBeat Community Rating for Unum Therapeutics (NASDAQ UMRX)
MarketBeat's community ratings are surveys of what our community members think about Unum Therapeutics and other stocks. Vote "Outperform" if you believe UMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
